Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:43:53 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:BLRX from 2023-05-04 to 2024-05-03 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-17 07:00U:BLRXNews ReleaseBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(TM) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
2024-04-10 07:00U:BLRXNews ReleaseBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
2024-04-01 09:00U:BLRXNews ReleaseBioLineRx Announces $6 Million Registered Direct Offering
2024-03-26 07:00U:BLRXNews ReleaseBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
2024-03-20 07:00U:BLRXNews ReleaseBioLineRx to Report 2023 Annual Financial Results on March 26, 2024
2024-03-04 07:00U:BLRXNews ReleaseBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
2024-02-28 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
2024-02-16 07:00U:BLRXNews ReleaseBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA ‚ ® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT ‚ ® and CIBMTR ‚ ®
2023-12-21 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
2023-11-20 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-11-13 07:00U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2023 Results on November 20, 2023
2023-10-31 09:00U:BLRXNews ReleaseBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
2023-10-31 09:00U:BLRXNews ReleaseBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
2023-10-12 07:00U:BLRXNews ReleaseBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
2023-09-28 07:00U:BLRXNews ReleaseBioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
2023-09-19 07:00U:BLRXNews ReleaseBioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
2023-09-11 07:00U:BLRXNews ReleaseBioLineRx Announces FDA Approval of APHEXDA ¢ „ ¢ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
2023-08-30 07:00U:BLRXNews ReleaseBioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-08-22 07:00U:BLRXNews ReleaseBioLineRx to Report Second Quarter 2023 Results on August 30, 2023
2023-07-17 07:00U:BLRXNews ReleaseBioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
2023-05-24 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-05-17 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2023 Results on May 24, 2023